Changeflow GovPing Healthcare & Life Sciences Guselkumab Persistence in UC and Crohn's Diseas...
Routine Notice Added Final

Guselkumab Persistence in UC and Crohn's Disease, Saudi Arabia

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

NIH registered ClinicalTrials.gov Study NCT07541261, an observational real-world study evaluating treatment persistence of guselkumab in participants with moderate to severe Crohn's disease or ulcerative colitis in Saudi Arabia. The study has no listed interventions and is classified as observational. Conditions studied include Colitis, Ulcerative and Crohn Disease.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

NIH registered a new observational clinical trial on ClinicalTrials.gov. Study NCT07541261 evaluates how long patients with moderate to severe Crohn's disease or ulcerative colitis continue taking guselkumab in a real-world setting in Saudi Arabia. No interventions are administered; the study observes treatment patterns. Healthcare providers and pharmaceutical companies conducting inflammatory bowel disease research should note this registry entry for awareness of ongoing real-world evidence studies in the MENA region.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi Arabia

Observational NCT07541261 Kind: OBSERVATIONAL Apr 21, 2026

Abstract

The main purpose of this study is to evaluate treatment persistence of guselkumab (that is how long a person keeps taking their prescribed medicine or continues with their treatment plan without stopping) in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.

Conditions: Colitis, Ulcerative, Crohn Disease

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 21st, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Clinical investigators
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Clinical trial registration Observational study Real-world evidence
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Pharmaceuticals Clinical Trials

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!